Chaim Indig Sells 5,295 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig sold 5,295 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total value of $123,108.75. Following the completion of the transaction, the chief executive officer now directly owns 1,223,736 shares of the company’s stock, valued at $28,451,862. The sale was disclosed in a filing with the SEC, which is available through this link.

Chaim Indig also recently made the following trade(s):

• On Monday, July 29th, Chaim Indig sold 7 shares of Phreesia stock. The stock was sold at an average price of $24.75, for a total value of $173.25.
• On Tuesday, July 16th, Chaim Indig sold 2,644 shares of Phreesia stock. The shares were sold at an average price of $23.74, for a total transaction of $62,768.56.

Phreesia Price Performance

NYSE PHR opened at $24.68 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.77 and a quick ratio of 1.77. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -11.37 and a beta of 0.93. The company has a 50 day simple moving average of $23.72 and a 200-day simple moving average of $22.75. Phreesia, Inc. has a 52-week low of $12.05 and a 52-week high of $29.16.

Institutional Trading of Phreesia

Institutional investors have recently bought and sold shares of the company. nVerses Capital LLC lifted its stake in Phreesia by 76.5% in the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after acquiring an additional 1,300 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Phreesia by 5,462.3% during the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock valued at $89,000 after purchasing an additional 3,769 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Phreesia in the 1st quarter valued at $169,000. Quadrature Capital Ltd acquired a new stake in shares of Phreesia in the 1st quarter valued at $202,000. Finally, Lombard Odier Asset Management USA Corp acquired a new position in Phreesia during the second quarter worth $202,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Analysts Set New Price Targets

PHR has been the subject of a number of recent analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $34.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 target price on shares of Phreesia in a report on Thursday, September 5th. Truist Financial boosted their target price on shares of Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Stephens reaffirmed an “overweight” rating and issued a $28.00 price target on shares of Phreesia in a report on Friday, May 31st. Finally, KeyCorp cut their price objective on Phreesia from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $29.42.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.